You are here: Industry Insights > DMD

News List

Cheaper drug just as effective protecting heart in Duchenne muscular dystrophy worldpharmanews
September 27, 2019
A new clinical trial conducted at The Ohio State University Wexner Medical Center found a cost-effective generic medication works just as well as a more expensive drug in preserving cardiovascular function in boys with ...
Cumberland Announces FDA Orphan Drug Grant Award for Ifetroban americanpharmaceuticalreview
September 26, 2019
Cumberland Pharmaceuticals announced FDA Orphan Drug Grant funding for a new Phase II clinical program. The Company has initiated the clinical development of ifetroban for the treatment ...
Solid tanks as safety scare again rocks DMD gene therapy fiercebiotech
May 15, 2019
A safety scare has rocked Solid Biosciences’ drive to get its Duchenne muscular dystrophy (DMD) gene therapy program back on track.
New drug for Duchenne muscular dystrophy clears phase 1 clinical trial worldpharmanews
February 22, 2019
Patients with Duchenne muscular dystrophy (DMD) have few treatment options.
Muscle stem cells can drive cancer that arises in Duchenne muscular dystrophy worldpharmanews
January 16, 2019
People with Duchenne muscular dystrophy (DMD) can develop an otherwise-rare muscle cancer, called rhabdomyosarcoma, due to the muscle cells' continuous work to rebuild the damaged tissue.
Pfizer ends two Duchenne muscular dystrophy drug trials pharmatimes
September 14, 2018
Pfizer is shutting down two clinical studies assessing the anti-myostatin monoclonal antibody domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD).
Sarepta shares surge after gene therapy leads to microdystrophin expression in DMD patients pharmafile
June 22, 2018
This week, shares in Sarepta Therapeutics rocketed by 80% after the company released preliminary data from a Phase 1/2a trial showing that its experimental gene therapy
Sarepta to Seek FDA Approval for Second DMD Treatment biospace
March 13, 2018
Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) is planning on seeking approval of a second treatment for Duchenne muscular dystrophy (DMD).
Solid Biosciences Discloses DMD Trial Setback Amid $125M IPO Push biospace
January 29, 2018
Solid Biosciences' failure to disclose some negative issues related to its work on a treatment for Duchenne muscular dystrophy (DMD) not only complicated its upcoming initial public offering (IPO), but is casting some shade on DMD research in general.
Astellas buys DMD drug in $450M mitochondrial takeover fiercebiotech
December 04, 2017
Astellas has acquired its partner Mitobridge in a deal worth up to $450 million. The takeover gives Astellas full control of a phase 1 Duchenne muscular dystrophy (DMD) drug in return for $225 million upfront and the same again down the line.

Previous page 1 2 3 Next page